Functional Characterization of Novel Mutations Affecting Survivin (BIRC5)-Mediated Therapy Resistance in Head and Neck Cancer Patients

Human Mutation

Volumn 34, Issue 2, 2013, Pages 395-404

  Knauer, Shirley K ^a   Unruhe, Britta ^a   Karczewski, Sarah ^a   Hecht, Rouven ^a   Fetz, Verena ^b   Bier, Carolin ^b   Friedl, Sandra ^b   Wollenberg, Barbara ^c   Pries, Ralph ^c   Habtemichael, Negusse ^b   Heinrich, Ulf Rüdiger ^b   Stauber, Roland H ^b  

^a UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

BIRC5; Cisplatin resistance; CRM1; Nuclear export; Survivin

Indexed keywords

CISPLATIN; SURVIVIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL TRANSPORT; CELLULAR DISTRIBUTION; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MITOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SOMATIC MUTATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; CYTOPLASM; DISEASE MODELS, ANIMAL; FATTY ACIDS, UNSATURATED; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MUTATION; NUCLEAR EXPORT SIGNALS; PROGNOSIS;

EID: 84873077232     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22249     Document Type: Article

References (56)

1. Altieri DC. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54.
2. Altieri DC. 2006. Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5:478-482.
3. Altieri DC. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61-70.
4. Altieri DC. 2011. Survivin and IAP proteins in cell-death mechanisms. Biochem J 430:199-205.
5. Argiris A, Karamouzis MV, Raben D, Ferris RL. 2008. Head and neck cancer. Lancet 371:1695-1709.
6. Barnes L, Eveson JW, Reichart P, Sidransky D. 2005. Pathology and genetics of head and neck tumours. WHO Press, Geneva, Switzerland.
7. Bier C, Knauer SK, Docter D, Schneider G, Kramer OH, Stauber RH. 2011a. The Importin-alpha/Nucleophosmin switch controls Taspase1 protease function. Traffic 12:703-714.
8. Bier C, Knauer SK, Klapthor A, Schweitzer A, Rekik A, Kramer OH, Marschalek R, Stauber RH. 2011b. Cell-based analysis of structure-function activity of threonine aspartase 1. J Biol Chem 286:3007-3017.
9. Brandl A, Wagner T, Uhlig KM, Knauer SK, Stauber RH, Melchior F, Schneider G, Heinzel T, Kramer OH. 2012. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol 4(5):284-293.
10. Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP. 2003. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116:2987-2998.
11. Chan KS, Wong CH, Huang YF, Li HY. 2011. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 1:e57.
12. Colnaghi R, Connell CM, Barrett RM, Wheatley SP. 2006. Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 281:33450-33456.
13. Connell CM, Colnaghi R, Wheatley SP. 2008. Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem 283:3289-3296.
14. Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, et al. 2008. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 68:5159-5166.
15. Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, Mann W, Kovacs AF, Stauber RH. 2007. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 211:532-540.
16. Engelsma D, Rodriguez JA, Fish A, Giaccone G, Fornerod M. 2007. Homodimerization antagonizes nuclear export of survivin. Traffic 8:1495-1502.
17. Fetz V, Bier C, Habtemichael N, Schuon R, Schweitzer A, Kunkel M, Engels K, Kovacs AF, Schneider S, Mann W, Stauber RH, Knauer SK. 2009. Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer 124:2033-2041.
18. Forastiere A, Weber R, Ang K. 2008. Treatment of head and neck cancer. N Engl J Med 358:1076; author reply 1077-1078.
19. Forastiere AA, Ang K, Brizel D, Brockstein BE, Dunphy F, Eisele DW, Goepfert H, Hicks WL, Jr., Kies MS, Lydiatt WM, Maghami E, McCaffrey T. et al. 2005. Head and neck cancers. J Natl Compr Canc Netw 3:316-391.
20. Habtemichael N, Heinrich UR, Knauer SK, Schmidtmann I, Bier C, Docter D, Brochhausen C, Helling K, Brieger J, Stauber RH, Mann WJ. 2010. Expression analysis suggests a potential cytoprotective role of Birc5 in the inner ear. Mol Cell Neurosci 45:297-305.
21. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
22. Kau TR, Way JC, Silver PA. 2004. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4:106-117.
23. Knauer SK, Bier C, Habtemichael N, Stauber RH. 2006. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 7:1259-1265.
24. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann ML, Hofmann WK, Kunkel M, et al. 2007a. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 6:1502-1509.
25. Knauer SK, Carra G, Stauber RH. 2005. Nuclear export is evolutionarily conserved in CVC paired-like homeobox proteins and influences protein stability, transcriptional activation, and extracellular secretion. Mol Cell Biol 25:2573-2582.
26. Knauer SK, Fetz V, Rabenstein J, Friedl S, Hofmann B, Sabiani S, Schröder E, Kunst L, Proschak E, Thines E, Kindler T, Scheider G, et al. 2011. Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors. PlosOne 6:e18253; DOI:10.1371/journal.pone.0018253.
27. Knauer SK, Heinrich UR, Bier C, Habtemichael N, Docter D, Helling K, Mann WJ, Stauber RH. 2010. An otoprotective role for the apoptosis inhibitor protein survivin. Cell Death Dis 1:e51.
28. Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rodel C, et al. 2007b. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 21:207-216.
29. Knauer SK, Mann W, Stauber RH. 2007c. Survivin's dual role: an export's view. Cell Cycle 6:518-521.
30. Krämer OH, Baus D, Knauer SK, Stein S, Jäger E, Stauber RH, Grez M, Pfitzner E, Heinzel T. 2006. Acetylation of Stat1 modulates NF-{kappa}B activity. Genes Dev 20:473-485.
31. Krämer OH, Knauer SK, Greiner G, Jandt E, Reichardt S, Gührs KH, Stauber RH, Böhmer FD, Heinzel T. 2009. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev 23:223-235.
32. Kuchelmeister HY, Gutschmidt A, Tillmann S, Knauer S, Schmuck C. 2012. Efficient gene delivery into cells by a surprisingly small three-armed peptide ligand. Chem Sci 3:996-1002.
33. Lehmann U, Bock O, Glockner S, Kreipe H. 2000. Quantitative molecular analysis of laser-microdissected paraffin-embedded human tissues. Pathobiology 68:202-208.
34. Lens SM, Rodriguez JA, Vader G, Span SW, Giaccone G, Medema RH. 2006a. Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres. Mol Biol Cell 17:1897-1909.
35. Lens SM, Vader G, Medema RH. 2006b. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 18:616-622.
36. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T, Kops G, Medema RH. 2003. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22:2934-2947.
37. Lippert BM, Knauer SK, Fetz V, Mann W, Stauber RH. 2007. Dynamic survivin in head and neck cancer: molecular mechanism and therapeutic potential. Int J Cancer 121:1169-1174.
38. Persson A, Backvall H, Ponten F, Uhlen M, Lundeberg J. 2002. Single cell gene mutation analysis using laser-assisted microdissection of tissue sections. Methods Enzymol 356:334-343.
39. Poon IK, Jans DA. 2005. Regulation of nuclear transport: central role in development and transformation? Traffic 6:173-186.
40. Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SB, Yoshida M, Keikhaee MR, Ogawa I, Takata T. 2011. Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol 46:263-270.
41. Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM. 2011. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer 10:639.
42. Riebe C, Pries R, Schroeder KN, Wollenberg B. 2011. Phosphorylation of STAT3 in head and neck cancer requires p38 MAPKinase, whereas phosphorylation of STAT1 occurs via a different signaling pathway. Anticancer Res 31:3819-3825.
43. Rodriguez JA, Lens SM, Span SW, Vader G, Medema RH, Kruyt FA, Giaccone G. 2006. Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. Oncogene 25:4867-4879.
44. Rodriguez JA, Span SW, Ferreira CG, Kruyt FA, Giaccone G. 2002. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 275:44-53.
45. Ruchaud S, Carmena M, Earnshaw WC. 2007. The chromosomal passenger complex: one for all and all for one. Cell 131:230-231.
46. Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, Spange S, Nonnenmacher F, Fetz V, Ginter T, Reichardt S, Liebmann C, et al. 2012. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget 3:31-43.
47. Stauber RH, Mann W, Knauer SK. 2007. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 67:5999-6002.
48. Stauber RH, Rabenhorst U, Rekik A, Engels K, Bier C, Knauer SK. 2006. Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic 7:1461-1472.
49. Vagnarelli P, Earnshaw WC. 2004. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 113:211-222.
50. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10:789-799.
51. Walch A, Komminoth P, Hutzler P, Aubele M, Hofler H, Werner M. 2000. Microdissection of tissue sections: application to the molecular genetic characterisation of premalignant lesions. Pathobiology 68:9-17.
52. Wang H, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A, Elenitoba-Johnson KS, Chin YE, Altura RA. 2010. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 285:36129-36137.
53. Wang Q, Wu PC, Roberson RS, Luk BV, Ivanova I, Chu E, Wu DY. 2011a. Survivin and escaping in therapy-induced cellular senescence. Int J Cancer 128:1546-1558.
54. Wang W, Wei Z, Lam TW, Wang J. 2011b. Next generation sequencing has lower sequence coverage and poorer SNP-detection capability in the regulatory regions. Sci Rep 1:55.
55. Xu L, Massague J. 2004. Nucleocytoplasmic shuttling of signal transducers. Nat Rev Mol Cell Biol 5:209-219.
56. Xu Y, Fang F, Ludewig G, Jones G, Jones D. 2004. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527-537.